Research in the heart of hematology: chronic myeloid leukemia 2017.
作者信息
Hehlmann Rüdiger
机构信息
Medizinische Fakultät Mannheim, Universität Heidelberg, Germany
出版信息
Haematologica. 2017 Mar;102(3):418-421. doi: 10.3324/haematol.2016.159848.
Abstract
摘要
相似文献
1
Research in the heart of hematology: chronic myeloid leukemia 2017.血液学核心领域的研究：2017年慢性粒细胞白血病
Haematologica. 2017 Mar;102(3):418-421. doi: 10.3324/haematol.2016.159848.
2
Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.跳出ABL1思考酪氨酸激酶抑制剂耐药性：SEPT9-ABL1融合蛋白的视角
Leuk Res. 2014 Dec;38(12):1399-400. doi: 10.1016/j.leukres.2014.09.015. Epub 2014 Oct 16.
3
Chromosomal aberrations and fusion genes in myeloid malignancies.髓系恶性肿瘤中的染色体异常和融合基因。
Expert Rev Hematol. 2012 Aug;5(4):381-93. doi: 10.1586/ehm.12.30.
4
The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
Leuk Lymphoma. 2013 Sep;54(9):2083-7. doi: 10.3109/10428194.2012.762649. Epub 2013 Feb 1.
5
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.在3个月和6个月时间点细胞遗传学和分子检测反应不一致的伊马替尼治疗的慢性髓性白血病患者后续获得最佳反应的概率降低。
Haematologica. 2015 Aug;100(8):e299-301. doi: 10.3324/haematol.2015.124685. Epub 2015 Mar 27.
6
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.慢性嗜酸性粒细胞白血病中的FIP1L1-PDGFRA和慢性髓性白血病中的BCR-ABL1影响不同的白血病细胞。
Leukemia. 2007 Mar;21(3):397-402. doi: 10.1038/sj.leu.2404510. Epub 2007 Jan 11.
7
Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.谜题的另一部分——慢性粒细胞白血病（CML）治疗中断前的最佳酪氨酸激酶抑制剂（TKI）选择。
Eur J Haematol. 2015 Mar;94(3):189-90. doi: 10.1111/ejh.12440.
8
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.伊马替尼——2015年用于慢性髓性白血病一线治疗的新型酪氨酸激酶抑制剂。
JAMA Oncol. 2015 May;1(2):143-4. doi: 10.1001/jamaoncol.2015.50.
9
Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.探索靶向BCR-ABL1的药物对慢性髓性白血病的治疗潜力。
Lancet Oncol. 2010 Nov;11(11):1010-1. doi: 10.1016/S1470-2045(10)70243-6. Epub 2010 Oct 19.
10
Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.来自细胞遗传学正常的慢性髓性白血病患者、对酪氨酸激酶抑制剂有完全细胞遗传学反应的CD34+/CD38-造血细胞中的克隆性染色体异常。
Leukemia. 2010 Aug;24(8):1525-1528. doi: 10.1038/leu.2010.123. Epub 2010 Jun 10.
引用本文的文献
1
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.在酪氨酸激酶抑制剂（TKI）治疗时代，基于细胞遗传学的慢性髓性白血病急变风险预测
Blood Adv. 2017 Dec 8;1(26):2541-2552. doi: 10.1182/bloodadvances.2017011858. eCollection 2017 Dec 12.
本文引用的文献
1
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.EUTOS 基于人群注册研究中 2904 例 CML 患者的治疗和结局。
Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.
2
Innovation in hematology. Perspectives: CML 2016.血液学创新。观点：2016年慢性粒细胞白血病
Haematologica. 2016 Jun;101(6):657-9. doi: 10.3324/haematol.2016.142877.
3
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.欧洲白血病网关于慢性髓性白血病治疗管理及不良事件避免的建议
Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28.
4
Moving treatment-free remission into mainstream clinical practice in CML.推动无治疗缓解进入 CML 的主流临床实践。
Blood. 2016 Jul 7;128(1):17-23. doi: 10.1182/blood-2016-01-694265. Epub 2016 Mar 24.
5
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗时代慢性髓性白血病染色体异常的风险分层
Blood. 2016 Jun 2;127(22):2742-50. doi: 10.1182/blood-2016-01-690230. Epub 2016 Mar 22.
6
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗时代慢性髓性白血病髓系与淋系原始细胞期额外染色体异常的差异影响
Leukemia. 2016 Jul;30(7):1606-9. doi: 10.1038/leu.2016.6. Epub 2016 Feb 3.
7
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.诊断时次要途径与主要途径核型不平衡对慢性粒细胞白血病预后的影响。
Ann Hematol. 2015 Dec;94(12):2015-24. doi: 10.1007/s00277-015-2494-9. Epub 2015 Sep 18.
8
Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?伊马替尼停药后慢性髓性白血病患者的肌肉骨骼疼痛：一种酪氨酸激酶抑制剂撤药综合征？
J Clin Oncol. 2014 Sep 1;32(25):2821-3. doi: 10.1200/JCO.2014.55.6910. Epub 2014 Jul 28.
9
Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.伊马替尼治疗持续时间与慢性髓性白血病患者估算肾小球滤过率降低有关。
Ann Oncol. 2011 Sep;22(9):2073-2079. doi: 10.1093/annonc/mdq715. Epub 2011 Feb 10.
10
Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.慢性髓系白血病的细胞遗传学和分子遗传学演变
Acta Haematol. 2002;107(2):76-94. doi: 10.1159/000046636.
Zotero 插件